Skip to main content
×
Home
    • Aa
    • Aa

Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis

  • David T. Kuhar (a1), David K. Henderson (a2), Kimberly A. Struble (a3), Walid Heneine (a4), Vasavi Thomas (a4), Laura W. Cheever (a5), Ahmed Gomaa (a6) and Adelisa L. Panlilio (a1)...
Abstract

This report updates US Public Health Service recommendations for the management of healthcare personnel (HCP) who experience occupational exposure to blood and/or other body fluids that might contain human immunodeficiency virus (HIV). Although the principles of exposure management remain unchanged, recommended HIV postexposure prophylaxis (PEP) regimens and the duration of HIV follow-up testing for exposed personnel have been updated. This report emphasizes the importance of primary prevention strategies, the prompt reporting and management of occupational exposures, adherence to recommended HIV PEP regimens when indicated for an exposure, expert consultation in management of exposures, follow-up of exposed HCP to improve adherence to PEP, and careful monitoring for adverse events related to treatment, as well as for virologie, immunologic, and serologic signs of infection. To ensure timely postexposure management and administration of HIV PEP, clinicians should consider occupational exposures as urgent medical concerns, and institutions should take steps to ensure that staff are aware of both the importance of and the institutional mechanisms available for reporting and seeking care for such exposures. The following is a summary of recommendations: (1) PEP is recommended when occupational exposures to HIV occur; (2) the HIV status of the exposure source patient should be determined, if possible, to guide need for HIV PEP; (3) PEP medication regimens should be started as soon as possible after occupational exposure to HIV, and they should be continued for a 4-week duration; (4) new recommendation—PEP medication regimens should contain 3 (or more) antiretroviral drugs (listed in Appendix A) for all occupational exposures to HIV; (5) expert consultation is recommended for any occupational exposures to HIV and at a minimum for situations described in Box 1; (6) close follow-up for exposed personnel (Box 2) should be provided that includes counseling, baseline and follow-up HIV testing, and monitoring for drug toxicity; follow-up appointments should begin within 72 hours of an HIV exposure; and (7) new recommendation—if a newer fourth-generation combination HIV p24 antigen-HIV antibody test is utilized for follow-up HIV testing of exposed HCP, HIV testing may be concluded 4 months after exposure (Box 2); if a newer testing platform is not available, follow-up HIV testing is typically concluded 6 months after an HIV exposure.

Copyright
Corresponding author
Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS A-31, Atlanta, GA 30333 (jto7@cdc.gov)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1. JD Siegel , E Rhinehart , M Jackson , et al.2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007;35(10 suppl 2):S65S164.

9. PL Havens ; American Academy of Pediatrics Committee on Pediatric AIDS. Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 2003;111(6 pt 1):14751489.

11. DM Bell . Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med 1997; 102(5B):915.

18. L Vidmar , M Poljak , J Tomazic , K Seme , I Klavs . Transmission of HIV-1 by human bite. Lancet 1996;347(9017):1762.

19. AK Deshpande , SK Jadhav , AH Bandivdekar . Possible transmission of HIV infection due to human bite. AIDS Res Ther 2011;8:16.

20. SM Andreo , LA Barra , LJ Costa , MC Sucupira , IE Souza , RS Diaz . HIV type 1 transmission by human bite. AIDS Res Hum Retroviruses 2004;20(4):349350.

21. G Ippolito , V Puro , G De Carli ; Italian Study Group on Occupational Risk of HIV infection. The risk of occupational human immunodeficiency virus infection in health care workers: Italian multicenter study. Arch Intern Med 1993;153(12):14511458.

22. DM Cardo , DH Culver , CA Ciesielski , et al; Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337(21):14851490.

23. ST Mast , JD Woolwine , JL Gerberding . Efficacy of gloves in reducing blood volumes transferred during simulated needle-stick injury. J Infect Dis 1993;168(6):15891592.

24. MR Furtado , DS Callaway , JP Phair , et al.Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340(21):16141622.

25. A Ibáñez , T Puig , J Elias , B Clotet , L Ruiz , MA Martinez . Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999;13(9):10451049.

27. R Tubiana , J Le Chenadec , C Rouzioux , et al.Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load < 500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS COI). Clin Infect Dis 2010;50(4):585596.

29. CC Shih , H Kaneshima , L Rabin , et al.Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 1991;163(3):625627.

34. JM Parkin , M Murphy , J Anderson , S El-Gadi , G Forster , AJ Pinching . Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000;355(9205):722723.

35. V Puro . Post-exposure prophylaxis for HIV infection: Italian Registry of Post-Exposure Prophylaxis. Lancet 2000;355(9214):15561557.

36. LM Lee , DK Henderson . Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf 2001;24(8):587597.

37. M Russi , M Buitrago , J Goulet , et al.Antiretroviral prophylaxis of health care workers at two urban medical centers. J Occup Environ Med 2000;42(11):10921100.

38. JR Garb . One-year study of occupational human immunodeficiency virus postexposure prophylaxis. J Occup Environ Med 2002;44(3):265270.

39. PR Grime , L Ris , C Binns , JR Carruthers , S Williams . Pan-Thames survey of occupational exposure to HIV and the use of post-exposure prophylaxis in 71 NHS trusts. J Infect 2001;42(l):2732.

43. DA Hawkins , D Asboe , K Barlow , B Evans . Seroconversion to HIV-1 following a needlestick injury despite combination postexposure prophylaxis. J Infect 2001;43(1):1215.

46. S Lockman , T Creek . Acute maternal HIV infection during pregnancy and breast-feeding: substantial risk to infants. J Infect Dis 2009;200(5):667669.

47. AP Kourtis . Antiretroviral drug use during pregnancy and risk of premature delivery: is there a connection? J Infect Dis 2010; 201(7):978980.

48. L Sarner , A Fakoya . Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002;78(1):5859.

49. L Mandelbrot , N Kermarrec , A Marcollet . Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003;17(2):272273.

51. N Ford , A Calmy , L Mofenson . Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and metaanalysis. AIDS 2011;25(18):23012304.

52. S Blanche , M Tardieu , V Benhammou , J Warszawski , P Rustin . Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 2006;20(13):16851690.

53. C Thorne , ML Newell . Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Sef 2007;30(3):203213.

54. M Mirochnick , T Thomas , E Capparelli , et al.Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009;53(3):11701176.

55. S Benaboud , A Pruvost , PA Coffie , et al.Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA study, step 2. Antimicrob Agents Chemother 2011;55(3):13151317.

56. RL Shapiro , MD Hughes , A Ogwu , et al.Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010;362(24):22822294.

57. S Dryden-Peterson , RL Shapiro , MD Hughes , et al.Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr 2011;56(5):428436.

58. JH Humphrey , E Marinda , K Mutasa , et al; ZVITAMBO Study Group. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. BMJ 2010;341:c6580.

60. S Masciotra , JS McDougal , J Feldman , P Sprinkle , L Wesolowski , SM Owen . Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 201l;52(suppl 1):S17S22.

61. BM Branson . The future of HIV testing. J Acquir Immune Defic Syndr 2010;55(suppl 2):S102S105.

62. P Chavez , L Wesolowski , P Patel , K Delaney , SM Owen . Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab combo assay. J Clin Virol 2011;52(suppl 1):S51S55.

64. CC Tsai , KE Follis , A Sabo , et al.Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270(5239):11971199.

65. RM Gulick , JW Mellors , D Havlir , et al.Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337(ll):734739.

66. M Hirsch , R Steigbigel , S Staszewski , et al.A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999;180(3):659665.

67. WH Wheeler , RA Ziebell , H Zabina , et al; Variant, Atypical, and Resistant HIV Surveillance Group. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.—2006. AIDS 2010;24(8):12031212.

69. R Scherzer , M Estrella , Y Li , et al.Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26(7):867875.

70. AM Cattelan , E Erne , A Salatino , et al.Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999;29(2):455456.

71. S Johnson , JG Baraboutis . Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000;284(21):27222723.

73. K Armstrong , R Görden , G Santorella . Occupational exposure of health care workers (HCWs) to human immunodeficiency virus (HIV); stress reactions and counseling interventions. Soc Work Health Care 1995;21(3):6180.

75. C Bentsen , L McLaughlin , E Mitchell , et al.Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma. J Clin Virol 2011; 52(suppl 1):S57S61.

76. R Ridzon , K Gallagher , C Ciesielski , et al.Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997;336(13):919922.

77. CA Ciesielski , RP Metler . Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Am J Med 1997;102(5B):115116.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Infection Control & Hospital Epidemiology
  • ISSN: 0899-823X
  • EISSN: 1559-6834
  • URL: /core/journals/infection-control-and-hospital-epidemiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 983 *
Loading metrics...

Abstract views

Total abstract views: 12193 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 25th May 2017. This data will be updated every 24 hours.